Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.

ABSTRACT:

Importance

Low-density lipoprotein cholesterol (LDL-C)-lowering therapies are a cornerstone of prevention in atherosclerotic cardiovascular disease. With the introduction of generic formulations and the release of new therapies, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, contemporary Medicare utilization of these therapies remains unknown.

Objective

To determine trends in utilization and spending on brand-name and generic LDL-C-lowering therapies and to estimate potential savings if all Medicare beneficiaries were switched to available therapeutically equivalent generic formulations.

Design, setting, and participants

This cross-sectional study analyzed prescription drug utilization and cost trend data from the Medicare Part D Prescript

SUBMITTER: Sumarsono A 

PROVIDER: S-EPMC7489407 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature